Cargando…
APOC3 Interference for Familial Chylomicronaemia Syndrome
Patients with familial chylomicronaemia syndrome (FCS) have severe hypertriglyceridaemia due to genetically absent lipolytic capacity. They have a poor response to conventional therapies. To reduce the risk of potentially fatal pancreatitis, the management of FCS relies principally on a strict low-f...
Autor principal: | Hegele, Robert A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Touch Medical Media
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835816/ https://www.ncbi.nlm.nih.gov/pubmed/36694895 http://dx.doi.org/10.17925/EE.2022.18.2.82 |
Ejemplares similares
-
Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score
por: Moulin, Philippe, et al.
Publicado: (2018) -
Adipokines and Incident Type 2 Diabetes in a Canadian Aborigine Population: The Sandy Lake Health and Diabetes Project
por: Ley, Sylvia H., et al.
Publicado: (2008) -
Metabolic Syndrome and Autoimmune Diabetes: Action LADA 3
por: Hawa, Mohammed I., et al.
Publicado: (2009) -
Incidence of type 2 diabetes in familial combined hyperlipidemia
por: Brouwers, Martijn C G J, et al.
Publicado: (2020) -
Clinical heterogeneity in monogenic chylomicronaemia
por: Heidemann, Britt E, et al.
Publicado: (2022)